Before taking Lotemax(loteprednol etabonat)

OPDUALAG demonstrated a significant improvement in progression-free survival in a clinical trial. 

Clinical Outcomes 

In the pivotal clinical trial (RELATIVITY-047), OPDUALAG significantly reduced the risk of disease progression or death compared to nivolumab alone. The median progression-free survival was 10.1 months versus 4.6 months, respectively. The overall response rate was also higher with the combination therapy (43% vs 33%), which included complete and partial responses. The overall survival results were not statistically significant at the interim analysis.